Bremelanotide
Also known as: Vyleesi, PT-141
Classification
Peptide
Regulatory Status
FDA-approved prescription product or labeled drug class
Mechanism Summary
Bremelanotide is represented by its commonly described melanocortin receptor agonist mechanism. This conservative launch record supports search and overlap detection, not medical recommendation.
Pathways
melanocortin-signalingsexual-functionmelanocortin receptor agonist
Benefits
Evidence reviewed for hypoactive sexual desire disorder per product label; BioStack presents this as educational reference, not a recommendation.
Drug Interactions
naltrexone — Potential additive or opposing effects may occur. (review)
References
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Bremelanotide
Educational reference only — not medical advice.